The missing work of collaboration: Using assemblages to rethink antidepressant action

Contemporary Drug Problems

Volumn 41, Issue 1, 2014, Pages 109-142

  Mcleod, Kim ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antidepressants; Assemblages; Australia; Deleuze; Qualitative research

Indexed keywords

EID: 84911870039     PISSN: 00914509     EISSN: 21631808     Source Type: Journal    
DOI: 10.1177/009145091404100106     Document Type: Article

References (73)

1. Anderson, B., Kearnes, M., McFarlane, C., & Swanton, D. (2012). Materialism and the politics of assemblage. Dialogues in Human Geography, 2(2), 212-215.
2. Australian Institute of Health and Welfare (AIWH). (2012). Australia’s Health 2012. Canberra: AIWH.
3. Barr, M., & Rose, D. (2008). The great ambivalence: Factors likely to affect service user and public acceptability of the pharmacogenomics of antidepressant medication. Sociology of Health & Illness, 30(6), 944-958.
4. Barthes, R. (1981). Camera lucida: Reflections on photography. New York: Hill and Wang.
5. Bennett, J. (2010). Vibrant matter: A political ecology of things. Durham: Duke University Press.
6. Beyondblue: The National Depression Initiative. (2012). Retrieved January, 2012, from http://www.beyondblue.org.au/index.aspx?link_id=89
7. Bissell, D. (2009). Travelling vulnerabilities: Mobile timespaces of quiescence. Cultural Geographies, 16(4), 427-445.
8. Braidotti, R., & Pisters, P. (2012). Introduction. In R. Braidotti & P. Pisters (Eds.), Revisiting normativity with Deleuze (pp. 1-8). London: Bloomsbury.
9. Buchanan, I. (1997). The problem of the body in Deleuze and Guattari, or, what can a body do? Body & Society, 3(3), 73-91.
10. Clarke, A. E. (2005). Situational analysis: Grounded theory after the postmodern turn. Thousand Oaks: Sage Publications.
11. Csordas, T. J. (1994). The sacred self: A cultural phenomenology of charismatic healing. Berkeley: University of California Press.
12. Delanda, M. (2006). A new philosophy of society: Assemblage theory and social complexity. London: Continuum.
13. Deleuze, G. (1992). Expressionism in philosophy: Spinoza (M. Joughin, Trans.). New York: Zone Books.
14. Deleuze, G., & Guattari, F. (1987). A thousand plateaus: Capitalism and schizophrenia. London: The Athlone Press.
15. Deleuze, G., & Parnet, C. (2006). Dialogues II (H. Tomlinson & B. Habberjan, Trans. Vol. London). London: Continuum.
16. Demant, J. (2009). When alcohol acts: An actor-network approach to teenagers, alcohol and parties. Body & Society, 15(1), 25-46.
17. Diprose, R., Stephenson, N., Hawkins, G., Mills, C., & Race, K. (2008). Biopolitical technologies of prevention. Health Sociology Review, 17(2), 141-150.
18. Dreimüller, N., Schlicht, K. F., Wagner, S., Peetz, D., Borysenko, L., Hiemke, C., et al. (2012). Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with major depression. Neuropharmacology, 62(1), 264-269.
19. Duff, C. (2012). Book review essay: After methods, after subjects, after drugs. Contemporary Drug Problems, 39, 265-287.
20. Duff, C. (2013). The social life of drugs. International Journal of Drug Policy, 24(3), 167-172.
21. Elliott, C. (2000). Pursued by happiness and beaten senseless. Hastings Center Report, 30(2), 7-12.
22. Elliott, C. (2003). Better than well: American medicine meets the American dream. New York: W. W. Norton and Company.
23. Ellis, P., & Smith, D. A. R. (2002). Treating depression: The beyondblue guidelines for treating depression in primary care. Medical Journal of Australia, 176 (10 Suppl), 77-83.
24. Fraser, M. (2003). Material theory: Duration and the serotonin hypothesis of depression. Theory, Culture and Society, 20(5), 1-26.
25. Fraser, S. (2013). The missing mass of morality: A new fitpack design for hepatitis C prevention in sexual partnerships. International Journal of Drug Policy, 24(3), 212-219.
26. Fraser, S., & Moore, D. (Eds.). (2011). The drug effect: Health, crime and society. Cambridge: Cambridge University Press.
27. Fullagar, S., & O’Brien, W. (2012). Problematizing the neurochemical subject of antidepressant treatment: The limits of biomedical response to women’s emotional distress. Health: An Interdisciplinary Journal for the Social Study of Health, Illness and Medicine, 17(1), 57-74.
28. Garfield, S. F., Smith, F. J., & Francis, S.-A. (2003). The paradoxical role of antidepressant medication: Returning to normal functioning while losing the sense of being normal. Journal of Mental Health, 12(5), 521.
29. Grosz, E. (2008). Chaos, territory, art. New York: Columbia University Press.
30. Healy, D. (2000). Good science or good business? Hastings Center Report, 30(2), 19-22.
31. Healy, D. (2004). Shaping the intimate: Influences on the experience of everyday nerves. Social Studies of Science, 34(2), 219-245.
32. Jackson, A. Y., & Mazzei, L. A. (2013). Plugging one text into another: Thinking with theory in qualitative research. Qualitative Inquiry, 19(4), 261-271.
33. Karp, D. (2006). Is it me or my meds? Living with antidepressants. Cambridge: Harvard University Press.
34. Keane, H. (2002). What’s wrong with addiction? New York: New York University Press.
35. Keane, H. (2011). The politics of visibility: Drug users and the spaces of drug use. International Journal of Drug Policy, 22, 407-409.
36. Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLOS Medicine, 5(2), 260-268.
37. Kleinman, A. (1986). Social origins of distress and disease: Depression, neurasthenia, and pain in modern China. New Haven: Yale University Press.
38. Lazzarato, M. (2006). Life and the living in the societies of control. In M. Fuglsang & B. M. Sorensen (Eds.), Deleuze and the social (pp. 171-190). Edinburgh: Edinburgh University Press.
39. Li, M. T. (2007). Practices of assemblage and community forest management. Economy and Society, 36(2), 263-293.
40. Lister, M., & Well, L. (2001). Seeing beyond belief: Cultural studes as an approach to analysing the visual. In T. Van Leeuwen & C. Jewitt (Eds.), Handbook of visual analysis (pp. 61-91). London: Sage Publications.
41. Malpass, A., Shaw, A., Sharp, D., Walter, F., Feder, G., Ridd, M., & Kessler, D. (2009). ‘Medication career’ or ‘moral career’? The two sides of managing antidepressants: A meta-ethnography of patients’ experience of antidepressants. Social Science & Medicine, 68(1), 154-168.
42. Marcus, G. E., & Saka, E. (2006). Assemblage. Theory Culture Society, 23(2-3), 101-106.
43. Massumi, B. (2002). Parables for the virtual: Movement, affect, sensation. Durham: Duke University Press.
44. Maxwell, J., & Miller, B. (2010). Categorizing and connecting strategies in qualitative data analysis. In P. Leavy & S. Hesse-Biber (Eds.), Handbook of emergent methods (pp. 461-477). New York: Guilford Press.
45. McFarlane, C. (2011). On context. City, 15(3-4), 375-388.
46. McManus, P., Mant, A., Mitchell, P., Britt, H., & Dudley, J. (2003). Use of antidepressants by general practitioners and psychiatrists in Australia. Australian & New Zealand Journal of Psychiatry, 37(2), 184-189.
47. Michael, M. (2012). Anecdote. In C. Lury & N. Wakefield (Eds.), Inventive methods:The happening of the social (pp. 25-35). London: Routledge.
48. Mol, A. (2008). The logic of care: Health and the problem of patient choice. London: Routledge.
49. Moyaihan, R. (2002). Selling sickness: GThe parmaceutical indusgtry and disease mogering. British Medican Journal, 324 73429, 886-991.
50. Race, K. (2011). Drug effects, performativity and the law. International Journal of Drug Policy, 22, 410-412.
51. Race, K. (2012). Framing responsibility: HIV, biomedical prevention and the performativity of the lLaw. Bioethical Inquiry, 9, 327-338.
52. Rose, G. (2007). Visual methodologies: An introduction to the interpretation of visual materials (2nd ed.). London: Sage Publications.
53. Rose, N. (1998). Inventing our selves: Psychology, power and personhood. Cambridge: Cambridge University Press.
54. Rose, N. (2003). Neurochemical selves. Society, 41(1), 46-59.
55. Rose N (2007) The politics of life itself: Biomedicine, Power and subjectivity in the twenty-first century. Princeton, NJ: Princeton University Press.
56. Rosengarten, M., & Michael, M. (2009). Rethinking the bioethical enactment of medically drugged bodies: Paradoxes of using anti-HIV drug therapy as a technology for prevention. Science as Culture, 18(2), 183-199.
57. Sedgwick, E. K. (2003). Touching feeling: Affect, pedagogy, performativity. Durham: Duke University Press.
58. Smardon, R. (2008). “I’d rather not take Prozac”: Stigma and commodification in antidepressant consumer narratives. Health:, 12(1), 67-86.
59. Stengers, I. (2000). The invention of modern science. Minneapolis: University of Minnesota Press.
60. Stephenson, N. (2005). Living history, undoing linearity: Memory-work as a research method in the social sciences. International Journal of Social Research Methodology, 8(1), 33-45.
61. The President’s Council on Bioethics. (2003). Beyond therapy: Biotechnology and the pursuit of happiness. Retrieved from www.bioethics.gov/reports/beyondtherapy
62. Thrift, N. (2003). Practising ethics. In M. Pryke, G. Rose & S. Whatmore (Eds.), Using social theory: Thinking through research. London: Sage Publications.
63. Vialou, V., Feng, J., Robison, A. J., & Nestler, E. J. (2013). Epigenetic mechanisms of depression and antidepressant action. Annual Review of Pharmacology and Toxicology, 53(1), 59-87.
64. Vitellone, N. (2010). Just another night in the shooting gallery? The syringe, space and affect. Environment and Planning D: Society and Space, 28, 867-880.
65. Vitellone, N. (2013). The empirical war on drugs. International Journal of Drug Policy, 24(3), 182-188.
66. Vöhringer, P. A., & Ghaemi, S. N. (2011). Solving the antidepressant efficacy question: Effect sizes in major depressive disorder. Clinical Therapeutics, 33(12), B49-B61.
67. Walkerdine, V. (2010). Communal beingness and affect: An exploration of trauma in an ex-industrial community. Body & Society, 16(1), 91-116.
68. Williams, J. W., & Mulrow, C. D. (2000). A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Annals of Internal Medicine, 132(9), 743.
69. Williams, S., & Keady, J. (2012). Centre stage diagrams: A new method to develop constructivist grounded theory—late-stage Parkinson’s disease as case exemplar. Qualitative Research, 12(2), 218-238.
70. Williams, S. J., Gabe, J., & Davis, P. (2008). The sociology of pharmaceuticals: Progress and prospects. Sociology of Health & Illness, 30(6), 813-824.
71. Wilson, E. (2006). The work of antidepressants: Preliminary notes on how to build an alliance between feminism and psychopharmacology. Biosocieties, 1, 125-131.
72. Wilton, R., & Moreno, C. M. (2012). Critical geographies of drugs and alcohol. Social & Cultural Geography, 13(2), 99-108.
73. World Health Organization. (2010). Mental health. Retrieved July 7, 2010, from http://www.who.int/mental_health/management/depression/definition/en/index.html